Idiopathic pulmonary fibrosis

The PBS subsidises nintedanib and pirfenidone for patients with idiopathic pulmonary fibrosis (IPF).

Patient eligibility

Treatment with nintedanib and pirfenidone can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, section 85 for a patient with IPF.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines restrictions for prescribing nintedanib and pirfenidone.


Initial treatment

Make all initial applications for authority approval to prescribe nintedanib or pirfenidone for the treatment of IPF in writing and either:

All applications must include the completed:

Continuing treatment

To make continuing applications for treatment with with nintedanib or pirfenidone call the PBS Complex Drugs Programs enquiry line.

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 November 2019